From the intestines of Japanese tree frogs, scientists have drawn an unlikely candidate in the long struggle against cancer: a single bacterium that, in mice, erased colorectal tumors entirely with one dose. Ewingella americana works not by brute chemical force but by exploiting the very conditions that make tumors dangerous — their oxygen-starved, immune-suppressed interiors — turning those conditions into a trap. The finding invites a humbling recognition that nature's smallest, most overlooked inhabitants may carry answers to the diseases that have most confounded human ingenuity.
Frog bacterium eliminates colorectal tumors in mice with single dose
The bacterium accumulated almost exclusively inside tumors and left healthy organs untouched.
Mark
Why does a bacterium from a frog's gut have any reason to attack a mouse tumor? That seems almost accidental.
Mimi
It's not accidental, but it's not intentional either. The bacterium doesn't "know" it's fighting cancer. What it does is exploit the tumor's own weaknesses—the low oxygen, the leaky blood vessels, the immunosuppressive proteins. The tumor creates conditions that happen to be perfect for this bacterium to survive and multiply. The immune attack that follows is just the body recognizing an invader.
Mark
So the tumor essentially sets its own trap.
Mimi
Exactly. And that's why the bacterium avoids healthy tissue. A normal organ has oxygen, intact blood vessels, and an active immune system. The bacterium can't establish itself there. It's not that the treatment is smart—it's that the tumor is vulnerable in very specific ways.
Mark
A single dose eliminated tumors completely. That's extraordinary. Why hasn't this been tried before?
Mimi
Most microbiome research has focused on changing the overall composition of gut bacteria or transplanting fecal material. This team took a step back and asked: what if we isolate a single strain, grow it in pure culture, and deliver it directly? It's a simpler idea, but it required screening 45 candidates and testing them methodically. That takes time and resources.
Mark
What worries you about moving this to humans?
Mimi
The obvious one: mice aren't people. Tumor biology is different. Human immune systems are more complex. We don't know if a single dose will work, or if the bacteria will behave the same way. There's also the question of whether patients will accept living bacteria as medicine. But the safety data here is clean—rapid clearance, no organ colonization, minimal inflammation. That's a good foundation.
Mark
Could this work for cancers that aren't solid tumors?
Mimi
That's an open question. The mechanism depends on the tumor's low-oxygen environment and leaky blood vessels. Blood cancers don't have those features in the same way. But the researchers are already planning tests on breast, pancreatic, and melanoma. If it works across multiple solid tumors, that would suggest the principle is robust.
Der Puls
- A single injection of a frog-derived bacterium eliminated 100% of colorectal tumors in mice — a result that outpaced both chemotherapy and leading immunotherapy drugs in direct comparison.
- The bacterium multiplies roughly 3,000-fold inside tumors within 24 hours, exploiting the low-oxygen environment that standard treatments struggle to penetrate.
- Rather than harming healthy tissue, E. americana accumulated almost exclusively in tumors, cleared from the bloodstream within a day, and caused only mild, temporary inflammation — a safety profile that surprised researchers.
- The immune system joins the assault: T cells, B cells, and neutrophils flood the tumor site, releasing inflammatory signals that amplify the kill and push cancer cells toward death.
- Researchers now plan to test the bacterium against breast, pancreatic, and melanoma cancers, and to explore whether pairing it with existing therapies could push outcomes even further.
From the intestines of Japanese tree frogs, scientists have drawn an unlikely candidate in the long struggle against cancer: a single bacterium that, in mice, erased colorectal tumors entirely with one dose. Ewingella americana works not by brute chemical force but by exploiting the very conditions that make tumors dangerous — their oxygen-starved, immune-suppressed interiors — turning those conditions into a trap. The finding invites a humbling recognition that nature's smallest, most overlooked inhabitants may carry answers to the diseases that have most confounded human ingenuity.
A bacterium recovered from the intestines of Japanese tree frogs has done something no single treatment has managed cleanly before: in laboratory mice with colorectal cancer, one injection of Ewingella americana eliminated every tumor. The microorganism attacked cancer cells directly and simultaneously triggered the immune system to join the assault — outperforming both standard chemotherapy and the checkpoint inhibitor drugs that have reshaped modern oncology.
The discovery came from an unconventional search. Instead of pursuing the fecal transplants and microbiome-reshaping strategies that have dominated gut-bacteria research, the team isolated 45 individual bacterial strains from amphibian intestines — tree frogs, fire belly newts, and grass lizards. Nine showed anticancer promise. E. americana was the standout.
Its power rests on a two-part mechanism. As a facultative anaerobe, the bacterium thrives in oxygen-scarce environments — exactly the conditions inside tumors — multiplying explosively and damaging cancer cells directly. Its presence also functions as an alarm: T cells, B cells, and neutrophils converge on the tumor, releasing inflammatory molecules that intensify the immune attack. Crucially, the bacterium found its way almost exclusively into tumor tissue, leaving healthy organs untouched. Leaky tumor blood vessels, suppressed local immunity, and the metabolic profile of cancer cells all act as a homing signal.
Safety data were reassuring. The bacteria cleared the bloodstream within a day, caused only brief, mild inflammation, and showed no signs of chronic toxicity over a 60-day observation window. Researchers are careful to frame these as mouse results — a proof of concept, not a cure — but the implications are wide. Testing is planned for breast, pancreatic, and melanoma cancers, and researchers will explore whether combining E. americana with existing therapies amplifies its effect. The work is also a quiet argument for biodiversity: the microbial worlds living inside amphibians may hold medicines that human ingenuity has not yet imagined.
A bacterium pulled from the intestines of Japanese tree frogs has accomplished something remarkable in laboratory mice: the complete elimination of colorectal tumors with a single injection. The microorganism, called Ewingella americana, not only destroyed cancer cells directly but also mobilized the immune system to finish the job. In head-to-head comparisons, it outperformed both standard chemotherapy and the newer immunotherapy drugs that have become pillars of cancer treatment.
The discovery emerged from an unconventional search. Rather than trying to reshape the entire ecosystem of gut bacteria or transplant fecal material from one organism to another—approaches that have dominated recent microbiome research—the team took a different path. They isolated 45 individual bacterial strains from the intestines of Japanese tree frogs, Japanese fire belly newts, and Japanese grass lizards. After screening these candidates for anticancer properties, nine showed promise. E. americana stood out as the strongest performer.
When researchers injected the bacterium intravenously into mice with colorectal cancer, something unexpected happened. A single dose produced a complete response rate of 100 percent—meaning tumors vanished entirely. The treatment surpassed the performance of anti-PD-L1 antibodies, which are checkpoint inhibitors that have transformed immunotherapy, and it outpaced liposomal doxorubicin, a chemotherapy workhorse. The researchers are careful to note that these results come from mice, not humans, but they describe the findings as an encouraging proof of concept for an entirely new class of cancer medicine.
The bacterium's success rests on a two-pronged attack. First, E. americana is a facultative anaerobe, meaning it can thrive in environments with or without oxygen. Inside tumors, where oxygen is scarce, the bacteria multiply explosively—roughly 3,000 times over within 24 hours of treatment. This explosive growth directly damages cancer cells. Second, the bacterium's presence acts as an alarm bell to the immune system. T cells, B cells, and neutrophils flood into the tumor, releasing inflammatory molecules like TNF-α and interferon-gamma that amplify the immune assault and drive cancer cells toward death.
What makes E. americana particularly elegant as a therapy is its precision. The bacterium accumulated almost exclusively inside tumors and left healthy organs untouched. Researchers identified several reasons for this tumor-specific targeting. The low-oxygen environment inside tumors naturally favors bacterial growth. Cancer cells produce a protein called CD47 that suppresses local immune activity, creating a permissive environment where bacteria can survive. Tumor blood vessels are unusually leaky, allowing circulating bacteria to slip into tumor tissue more easily than into healthy tissue. And tumors undergo metabolic changes that provide nutrients the bacteria need. Together, these factors act as a homing beacon, concentrating the treatment exactly where it's needed.
Safety data provided additional reassurance. The bacteria were rapidly cleared from the bloodstream, with a half-life of about 1.2 hours, becoming undetectable within a day. No bacterial colonization appeared in the liver, spleen, lungs, kidneys, or heart. The treatment triggered only mild, temporary inflammation that resolved within three days. Over a 60-day observation period, researchers found no signs of chronic toxicity.
The implications extend far beyond colorectal cancer. The team plans to test whether E. americana works against breast cancer, pancreatic cancer, and melanoma. They will also explore whether the bacterium becomes even more effective when combined with existing chemotherapy or immunotherapy drugs, and whether delivering it directly into tumors or using fractional dosing improves outcomes. The work also underscores a broader principle: that nature's biodiversity—in this case, the microbial communities living inside amphibians—may harbor solutions to diseases that have resisted conventional medicine. For patients facing cancers that are difficult to treat, this line of research opens a door that was not there before.
Bemerkenswerte Zitate
The researchers emphasize that these findings are limited to mice, but they believe the results provide an encouraging proof of concept for developing new bacterial cancer therapies.— Research team
Möchten Sie die ganze Geschichte?
Das Original lesen bei ScienceDaily ↗
Health & Medicine